

The invention concerns a T-cell based immunotherapy using peptides which are derived from human membrane protein desmoglein. By applying a medical preparation including a peptide or a combination of peptides, a specific immunological tolerance is triggered. Therefore, the clinical signs of pemphigus vulgaris disease improve, because the base for disease is deprived.
Further information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.